ArticleStatistics in medicine2014
Dose finding with drug combinations in cancer phase I clinical trials using conditional escalation with overdose control.
Article in Statistics in medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 58 citations in OpenAlex.
- Toxicity Adaptive Lists Design: A Practical Design for Phase I Drug Combination Trials in Oncology.JCO precision oncology · 2024Article
- Development of consensus-driven SPIRIT and CONSORT extensions for early phase dose-finding trials: the DEFINE study.BMC medicine · 2023Review
- Modeling synergism in early phase cancer trials with drug combination with continuous dose levels: is there an added value?Brazilian journal of biometrics · 2022Article
- Combining cytotoxic agents with continuous dose levels in seamless phase I-II clinical trials.Journal of the Royal Statistical Society. Series C, Applied statistics · 2022Article
- A nonparametric Bayesian method for dose finding in drug combinations cancer trials.Statistics in medicine · 2022Article
- Accuracy and Safety of Novel Designs for Phase I Drug-Combination Oncology Trials.Statistics in biopharmaceutical research · 2022Article
- Adaptive Bayesian phase I clinical trial designs for estimating the maximum tolerated doses for two drugs while fully utilizing all toxicity information.Biometrical journal. Biometrische Zeitschrift · 2021Article
- Adding flexibility to clinical trial designs: an example-based guide to the practical use of adaptive designs.BMC medicine · 2020Article
- A surface-free design for phase I dual-agent combination trials.Statistical methods in medical research · 2020Article
- A Bayesian Adaptive Design in Cancer Phase I Trials Using Dose Combinations with Ordinal Toxicity Grades.Stats · 2020Article
- Cancer phase I trial design using drug combinations when a fraction of dose limiting toxicities is attributable to one or more agents.Biometrical journal. Biometrische Zeitschrift · 2019Article
- AAA: triple adaptive Bayesian designs for the identification of optimal dose combinations in dual-agent dose finding trials.Journal of the Royal Statistical Society. Series C, Applied statistics · 2019Article
- Two-stage design for phase I-II cancer clinical trials using continuous dose combinations of cytotoxic agents.Journal of the Royal Statistical Society. Series C, Applied statistics · 2019Article
- Accelerating anticancer drug development - opportunities and trade-offs.Nature reviews. Clinical oncology · 2018Review
- A Bayesian Adaptive Design in Cancer Phase I Trials using Dose Combinations in the Presence of a Baseline Covariate.Journal of probability and statistics · 2018Article
- A Bayesian adaptive design for cancer phase I trials using a flexible range of doses.Journal of biopharmaceutical statistics · 2018Article
- A Bayesian adaptive design for estimating the maximum tolerated dose curve using drug combinations in cancer phase I clinical trials.Statistics in medicine · 2017Article
- Identifying a maximum tolerated contour in two-dimensional dose finding.Statistics in medicine · 2017Article
- Dose Finding for Drug Combination in Early Cancer Phase I Trials using Conditional Continual Reassessment Method.Journal of biometrics & biostatistics · 2017Article
- A Bayesian Adaptive Design for Combination of Three Drugs in Cancer Phase I Clinical Trials.American journal of biostatistics · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
We present a Bayesian adaptive design for dose finding of a combination of two drugs in cancer phase I clinical trials. The goal is to estimate the maximum tolerated dose (MTD) as a curve in the two-dimensional Cartesian plane. We use a logistic model to describe the relationship between the doses of the two agents and the probability of dose limiting toxicity. The model is re-parameterized in terms of parameters clinicians can easily interpret. Trial design proceeds using univariate escalation with overdose control, where at each stage of the trial, we seek a dose of one agent using the current posterior distribution of the MTD of this agent given the current dose of the other agent. At the end of the trial, an estimate of the MTD curve is proposed as a function of Bayes estimates of the model parameters. We evaluate design operating characteristics in terms of safety of the trial design and percent of dose recommendation at dose combination neighborhoods around the true MTD curve. We also examine the performance of the approach under model misspecifications for the true dose-toxicity relationship.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.